RYR2 and catecholaminergic polymorphic ventricular tachycardia 1: Interestingly, a recent study performed by Preininger and colleagues revealed the inadequacy of β-blocker treatment by nadolol in one patient affected by a novel mutation in RYR2 that causes CPVT1 [130].